5Brockmann J,Emparan C,Hernandez CA,et al.Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.Anticancer Res,2000,20(6):4941-4947.
二级参考文献11
1[1]Plebani M, Basso D, Navaglia F, et al. Is CA242 really a new tumor marker for pancreatic adenocarcinoma? Oncology, 1995, 52: 19.
2[2]Lundin J, Roberts PJ, Kuusela P, et al. Prognostic significance of serum CA242 in pancreatic cancer. A comparison with CA19-9. Anticancer Res, 1995, 15: 2181.
3[3]Cappelli G, Paladini S, D'Agata A, et al. Tumor markers in the diagnosis of pancreatic cancer. Tumori, 1999, 85(1, Suppl.1): S19.
4[4]Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol, 1999, 10(Suppl.4): 145.
5Banfi G, Bravi S, Ardemagni A, et al.CA19-9,CA242 and CEA in the diagnosis and follow-up of pancreatic cancer.Int J Biol Markers,1996,2:77-81.
6Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer, 1996, 3:372-376.
7Nishida K, Kaneko T, Yoneda M, et al. Doubling time of serum CA19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.J Surg Oncol, 1999, 3:140-146.
8Kim H J,Kim M H,Myung S J,et al.A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer:analysis using a receiver operating characteristic curve.Am J Gastroenterol, 1999, 7:1941-1946.
8Tabuehi Y, Deguchi H, Imanishi K, et al. Immunohistochemical studies on the main entrance-route of CA19-9 into the periphoral venous blood of gastric cancer patients [ J ]. Cancer, 1990,7 ( 66 ) : 1529.
9Nissenson AR, Strobos J. Iron deficiency in patients with renal failure [ J ]. Kidney Int, 1999,55 ( suppl 69) : S18 - 21.
